This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Oxygen Biotherapeutics And U.S. Navy Expand Collaboration With Cooperative Research & Development Agreement To Study Oxycyte® For Treatment Of Hemorrhagic Shock

Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a development stage biomedical company focused on developing oxygen-carrying intravenous and topical products, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Unit of San Antonio (NAMRU-SA) to assess the safety and efficacy of Oxycyte ® as well as hemoglobin-based oxygen carriers (HBOC) as potential resuscitation treatments for hemorrhagic shock. This latest CRADA is in addition to separate, ongoing research programs in which the U.S. Navy is exploring the therapeutic potential of Oxycyte in the areas of decompression sickness and traumatic brain injury.

Circulatory system collapse (shock) following acute hemorrhage continues to be the leading cause of preventable battlefield death and is also frequently seen in the civilian population in victims of vehicular accidents and shootings. Hemorrhagic shock is characterized by hemodynamic instability that leads sequentially to decreases in oxygen delivery, lowered tissue perfusion, cellular hypoxia, organ damage, and, often, death. The success of current treatment modalities, which include introduction of IV fluids and blood products, are time dependent and often problematic, particularly on the battlefield. Intravenous oxygen–carrying therapeutic agents have the potential to improve survival by providing oxygen to tissues, maintaining blood pressure, and reducing or preventing hemorrhagic shock following acute battlefield injury prior to hospitalization.

Per the terms of this most recent CRADA, NAMRU-SA will conduct a multi-phased, three-year research program to study several oxygen based therapies in rat and swine models of hemorrhagic shock. Endpoints of the research include:

  • direct tissue arteriole diameter measurements to assess vasoactivity
  • comparing standard measurement of oxygen delivery to direct tissue oxygen concentrations
  • determining if there are any effects of oxidative stress, inflammation and apoptosis

Oxygen Biotherapeutics will provide NAMRU-SA with existing information related to the development of its perfluorocarbon-based drug candidate, Oxycyte, including safety data from the company’s studies in animals and humans. In addition, Oxygen Biotherapeutics will provide ongoing guidance regarding optimal approaches to Oxycyte administration and dosing. Oxycyte will be transferred from the company to the NAMRU-SA under a separate material transfer agreement (MTA). All reimbursements under the MTA will be used to offset our ongoing development costs.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs